GSK agreed to buy an experimental medicine from a Cambridge biotech for as much as $2 billion to shore up its drug pipeline and muscle into the promising field of liver therapies. The treatment ...

As pharma companies try to get more compounded GLP-1 users on branded versions of the drugs, they’re embracing certain ...

GSK Plc halted a trial following positive results for an oral antibiotic to treat complicated urinary tract infections that could replace an intravenous medicine that is typically used. The ...

Both companies viewed the early end to the PIVOT-PO trial as a positive development, with GSK saying it would work with US regulatory authorities to move the treatment forward in 2025. GSK and Spero ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa ...

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a common form of liver disease, in a deal worth up to $2 billion. GSK said in ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of GSK (GSK) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more ...

(Alliance News) - GSK announced on Wednesday that it has agreed with Boston Pharmaceuticals to buy steatotic liver disease medication efimosfermin alfa. The London-based pharmaceutical company ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials. Belrestotug, a human IgG1 antibody ...

Soft earnings didn't appear to concern GSK plc's (LON:GSK) shareholders over the last week. Our analysis suggests that while the profits are soft, the foundations of the business are strong.

Shares of Spero Therapeutics gained after the company and GSK ended their trial for a treatment for complicated urinary tract infections early after it met its primary endpoint. The stock more ...